Giugliano, Federicaa,b; Curigliano, Giuseppea,b; Tarantino, Paoloa,b,c,d
aDivision of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS
bDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy
cDana-Farber Cancer Institute
dHarvard Medical School, Boston, Massachusetts, USA
Received 18 November 2022 Accepted 7 December 2022.
Correspondence to Paolo Tarantino, MD, PhD, Division of Early Drug Development for Innovative Therapy, IEO, European Institute of Oncology IRCCS, Via Ripamonti 435 20141, Milano Italy, Tel: +39 02 57489 599; e-mail: [email protected]